Antitumoral Activity of Rapamycin in Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex

This publication has 12 references indexed in Scilit:

• Embolization of Renal Angiomyolipomata in Patients With Tuberous Sclerosis Complex
  American Journal of Kidney Diseases, 2006
• Dual Inhibition of mTOR and Estrogen Receptor SignalingIn vitroInduces Cell Death in Models of Breast Cancer
  Clinical Cancer Research, 2005
• Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF
  Blood, 2005
• Phosphorylation and Functional Inactivation of TSC2 by Erk: Implications for Tuberous Sclerosisand Cancer Pathogenesis
  Published by Elsevier ,2005
• Effects of Rapamycin in the Eker Rat Model of Tuberous Sclerosis Complex
  Pediatric Research, 2005
• Two‐year incidence of malignancy in sirolimus‐treated renal transplant recipients: results from five multicenter studies*
  Clinical Transplantation, 2004
• Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma
  The Lancet, 2003
• Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor
  Nature Medicine, 2002
• Tuberous Sclerosis Complex Consensus Conference: Revised Clinical Diagnostic Criteria
  Journal of Child Neurology, 1998
• Management of renal angiomyolipoma: analysis of 15 cases.
  European Urology, 1998